After Eli Lilly (LLY) and ProQR Therapeutics (PRQR) announced the expansion of their licensing and collaboration agreement to add five more targets, JMP Securities analyst Jonathan Wolleben said the expansion provides non-dilutive cash for ProQR as well as "further external validation" for the Axiomer RNA-editing technology. While telling investors that he is looking forward to learning more about the liver targets at an R&D day in Q1, which "could provide the opportunity to be more constructive on the internal pipeline," until he has that visibility he views shares as fairly valued at these levels and keeps a Market Perform rating on ProQR.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- PRQR Skyrockets Following Expanded Collaboration with LLY
- Eli Lilly, ProQR expand genetic medicines licensing and collaboration agreement
- Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration
- Eli Lilly’s Mounjaro, Trulicity added to FDA shortage list, STATNews reports
- Biotech Alert: Searches spiking for these stocks today